Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 11
Submit an article Journal homepage
474
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

Yue Hua Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, ChinaView further author information
,
Haijun Lib Guangdong Raynovent Biotech Co., Ltd, Guangzhou, ChinaView further author information
,
Min Wua Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, ChinaORCID Iconhttps://orcid.org/0000-0001-9152-3402View further author information
ORCID Icon,
Hong Zhanga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, ChinaView further author information
,
Yanhua Dinga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, ChinaView further author information
,
Yun Pengb Guangdong Raynovent Biotech Co., Ltd, Guangzhou, ChinaView further author information
,
Xiaojiao Lia Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, ChinaView further author information
&
Zhenxiang Yuc Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1159-1167 | Received 11 Mar 2021, Accepted 14 Oct 2021, Published online: 01 Nov 2021

References

  • Paules C, Subbarao K. Influenza. Lancet. 2017;390(10095):697–708.
  • Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol. 2017 Jul;39(5):541–550. Epub 2017 May 29.
  • National Health and Planning Commission. Protocols for the diagnosis and treatment of influenza (revised 2018 edition). Chin J Clin Infect Dis 2019; 12(1): 1–5
  • Mezhenskaya D, Isakova-Sivak I, Rudenko L. M2e-based universal influenza vaccines: a historical overview and new approaches to development. J Biomed Sci. 2019 Oct 19;26(1):76.
  • Yoo SJ, Kwon T, Lyoo YS. Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure. Clin Exp Vaccine Res. 2018;7(1):1–15.
  • Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci. 2014;1323(1):115–139.
  • 2009 H1N1-Related Deaths. Hospitalizations and cases: details of extrapolations and ranges: united States, Emerging Infections Program (EIP) data. 2009 [cited 2009 Nov 12]. Available from: https://www.cdc.gov/h1n1flu/pdf/details_eip_methods_plus_schematic.pdf
  • Wei P, Cai Z, Hua J, et al. Pains and gains from China’s experiences with emerging epidemics: from SARS to H7N9. Biomed Res Int. 2016 Jul;20:2016.
  • Feng L, Shay DK, Jiang Y, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008. Bull World Health Organ. 2012;90(4):279–88B.
  • Dunning J, Baillie JK, Cao B, et al. Antiviral combinations for severe influenza. Lancet Infect Dis. 2014;14(12):1259–1270.
  • Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363–1373.
  • Davidson S. Treating Influenza infection, from now and into the future. Front Immunol. 2018Sep10;9:1946. eCollection 2018.
  • Jefferson T, Demicheli, V, and Deeks, JJ, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev. 2002;3: CD001169 .
  • Al Khatib HA, Al Thani, AA, and Gallouzi, I, et al. Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017. BMC Infect Dis. 2019 Apr 11;19(1):314.
  • Trevejo JM, Asmal M, Vingerhoets J, et al. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2018;23(4):335–344.
  • Kikuchi T, Watanabe A. Baloxavir heralds a new era in influenza virus biology. Respir Investig. 2019Jan;57(1):1–2. Epub 2018 Nov 3.
  • Deleu S, Kakuda, TN, and Spittaels, K, et al. Single‐and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers. Br J Clin Pharmacol. 2018;84(11):2663–2672.
  • Finberg RW, Lanno, R, and Anderson, D et al. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2019; 219(7): 1026–1034.
  • Trainor GL. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov. 2007;2(1):51–64.
  • Buscher B, Laakso, S, and Mascher, H et al,. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis. 2014; 6(5): 673–82.
  • European Medicines Agency. Committee for human medicinal products. Guideline on the Bioanalysis for plasma protein binding studies in drug discovery & drug development investigation of drug interactions, Final. PMP/EWP/560/95/Rev. 1 Corr.*. London: European Medicines Agency; 2012.
  • US Department of Health and Human Services, US FDA. Center for drug evaluation and research guidance for industry, drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. FDA: Draft Guidance; 2012.
  • Bekersky I, Fielding RM, Dressler DE, et al. protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002;46(3):834–840.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.